Journal of Current Medical Research and Opinion
Received 13-05-2024 | Revised 14-05-2024 | Accepted 08-06-2024 | Published Online 09-06-2024

DOI: https://doi.org/10.52845/CMRO/2024/7-6-13 **ISSN (O) 2589-8779 | (P) 2589-8760**

CMRO 07 (06), 2749-2760 (2024)

Original Research

Investigating the Role of the Surface Protein Esp in the Pathogenesis of Enterococcal Urinary Tract Infections: Pathogenicity, Epidemiology, Prophylaxis, and Treatment

Sarah Hadi Saleh Nassif Al-Qaisi[1], Safa Hussein Aliwi Al-Jumaili[2], Doha Thamer Abbas Kazem Al-Sultani[3], Ruaa Abass Ali AL-Tamimi[4]

[1]University of Anbar, College of Science, Department of Biology, Iraq
[2]University of Anbar, College of Science, Department of Biology, Iraq
[3]University of Babylon, College of Science, Department of Biology, Iraq
[4]Al-Mustansiriya University, College of Science, Department of Biology, Iraq

Abstract:

There are a vast variety of uropathogens that can cause urinary tract infections (UTIs), which rank high among the infectious disease burden on a global scale. Enterococci are uropathogens that live in the gastrointestinal system and are Gram-positive, facultative anaerobic commensal organisms. Endocarditis and urinary tract infections (UTIs) are among the many healthcare-associated illnesses caused by Enterococcus spp. The overuse of antibiotics, particularly by enterococci, has led to a rise of multidrug-resistant bacteria in recent years. Furthermore, enterococcal infections are particularly difficult because of the enterococci's inherent resistance to antibiotics, genetic malleability, and ability to thrive in harsh settings. The overarching goal of this review is to bring attention to enterococci by highlighting their pathogenicity, epidemiology, and treatment suggestions (based on the most current guidelines).

Keywords: Enterococcal UTI, Pathogenicity, Epidemiology, Treatment

Introduction:

Among all age groups and genders, urinary tract infections (UTIs) rank high among the most prevalent types of infections. In 2019, more than 200,000 people lost their lives as a result of UTIs, which affected more than 404.6 million people worldwide. With over $2.8 billion spent in 2011, the financial impact of hospitalisations linked with UTIs is enormous. A global increase has been observed in the rates of illness, mortality, and disability-adjusted life-years, according to data obtained from the Global Health Data Exchange between 1990 and 2019 [1-3]. Research into the causes and potential solutions to UTIs must continue because of the damage they do to people's health, healthcare systems, and entire populations. There is a further categorization for UTIs: simple and complex. In males and non-pregnant females, a lower urinary tract infection (UTI) is considered to be uncomplicated or simple [4]. Atypical organisms, high-risk patients (due to factors such as pregnancy, comorbidities, immunosuppression, etc.), or infections involving

the upper urinary tract are the hallmarks of complicated UTIs. With roughly 80% of cases, Escherichia (E.) coli is the most prevalent bacterial pathogen responsible for UTIs. The remaining 20% are mainly made up of enterococcus (E.) faecalis, Staphylococcus (S.) saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis [5].

Urinary tract infections (UTIs) are among the most prevalent bacterial diseases that people frequently suffer from. Despite the fact that its formation is attributed to several microorganisms, The most common bacteria that cause UTIs are Staphylococcus saprophyticus, Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus mirabilis. There are more than 8 million annual hospital admissions attributed to urogenital tract infections. 5Many Enterococcus faecalis isolates are resistant to standard treatments, making these infections extremely difficult to treat at times [6, 7]. When it comes to Enterobacteriaceae, antimicrobial resistance (AMR) is a major issue for public health, especially in underdeveloped nations. Because of the uropathogenic increasing recurrence rate and resistance to antibiotic treatment, the financial burden of these diseases is rising dramatically.

Enterococci are Gram-positive, facultative anaerobic commensal organisms of the GI tract and recognised uropathogens; they are the primary focus of this research. From endocarditis to urinary tract infections (UTIs), Enterococcus spp. has emerged as a major culprit in healthcare-associated illnesses [8, 9]. The ability of enterococci to proliferate in harsh settings and their resistance to both intrinsic and multidrug antibiotics make them an interesting issue when it comes to infections.

A urinary tract infection (UTI) can be caused by any number of gram-positive pathogenic bacteria, although the most prevalent ones are Staphylococcus saprophyticus and Enterococci.A urinary tract infection (UTI) can originate from a strain of the bacterium Enterococcus, which has been associated with gastrointestinal (GIT) infections. Some uropathogens and gastrointestinal bacteria may be able to get antibiotic-resistance genes from bacteria that are already resistant to them. Enterococcus faecalis and Enterococcus faecium are the two species of Enterococcus that typically cause enterococcal infections [10, 11]. The rate of antibiotic resistance is increasing at a far higher rate than the rate of sickness globally, specifically among enterococci. When resistance genes (RG) are located on chromosomes or when determinants responsible for resistance are acquired on plasmids (or transposons), enterococci seem to be rebellious. Many antibiotics are unable to eradicate infections caused by enterococcal bacteria.

The Matrix framework organisms:

Over the past four decades, researchers have noticed and investigated the production of biofilms by enterococcus. Following their description in the mid-1980s, researchers have dug deep into their evolution and the ways in which they affect virulence and resistance patterns [12, 13]. The creation of biofilms is known to be a complex process that involves multiple factors, all of which work together to make bacteria more dangerous and resistant to antibiotics. E. faecalis biofilm development is characterised by four phases, as defined by Ch'ng et al.: adhesion, microcolony production, biofilm maturation, and dispersal. Surface adhesins, proteases, glycolipids, and aggregation substances and enterococcal surface proteins all play a role in attachment. Once adhered, E. faecalis bacteria produce a biofilm matrix that microcolony aggregates use for multiplication. Subsequently, extracellular matrix components like modified lipids, glycoproteins, lipoteichoic acid, extracellular proteases, and extracellular DNA are produced as this biofilm matrix develops. Microcolonies experience environmental stress as they develop and expand due to factors such as local nutrient shortages, overcrowding, hypoxia, and waste accumulation [14–16]. As a last stage in biofilm creation, the stress response causes a change in

gene expression from maturation to dispersal. By breaking the microcolony wall and liquefying the biofilm core, individual bacteria are able to escape and establish new colonies during dispersal. Even though E. faecalis and E. faecium share many similarities in their biofilm forming processes, they are not identical. Though they both create biofilm, the way E. faecalis and E. faecium protect themselves is distinct. In contrast to E. faecium, which makes an impenetrable film, E. faecalis carries antibiotic-resistant genes in its film [17]. Enterococcus spp., particularly those isolated from the urinary tract, seem to be characterised by adhesion and biofilm development. It is already challenging to treat biofilms because they encourage polymicrobial colonisation with other species, such as E. coli, which has been discovered in co-isolates with E. faecalis in UTIs. Through immunomodulation and inhibition, E. coli's pathogenicity is amplified in this mutualistic association with E. Faecalis. According to research conducted by Tien et al., E. faecalis can avoid being recruited and activated by immune cells such macrophages by blocking the signalling of nuclear factor kappa B (NF-κB) [18, 19]. The release of gelatinase is another way that immunomodulation can be achieved; this enzyme cleaves complement components (C3, C3a, and C5a). E. faecalis is able to avoid detection by the innate immune system because of this. Tien et al. also looked into the connection between this communalistic bond and CAUTIs, or catheter-associated urinary tract infections. They discovered that compared to CAUTIs produced solely by E. coli, multimicrobial CAUTIs containing both E. faecalis and E. coli had a reduced number of macrophages.

Criteria for Virulence:

There are a number of additional mechanisms, called virulence factors, that Enterococcus uses to make itself more harmful [6,7]. Virulence factors are compounds that help bacteria survive and colonise their host environment, as well as increase their pathogenicity [10]. Isolates of Enterococcus spp. from the urine often contain virulence factors such as aggregation compounds, gelatinase, TcpF, collagen binding protein, pilin gene clusters (PGCs), and enterococcal surface proteins [20]. Evidence suggests that enterococcal surface proteins (Esp) facilitate biofilm development by enhancing initial adhesion. Esp has been detected in Escherichia coli and Escherichia faecium. An additional investigation into the function of Esp in UTIs caused by E. faecalis was carried out by Shankar et al., who discovered that Esp plays an essential role during colonisation. An essential surface adhesion, aggregation substance (AS) facilitates bacterial aggregation, mediates adherence to host cells, and encourages cell conjugation with plasmids that respond to pheromones [21]. It is worth noting that certain enterococci species exhibit a higher level of one virulence factor than others. For instance, a collagen-binding protein was found in E. faecalis urine isolates at a high frequency.

Physiology:

Not only does E. faecalis not create gas when fermenting glucose, but it also does not catalyse a process when exposed to hydrogen peroxide. Although it does not dissolve gelatin, it does reduce litmus milk. Its growth pattern in nutrient broth is commensurate with that of a facultative anaerobe. Energy sources such as glycerol, lactate, malate, citrate, arginine, agmatine, and many keto acids are catabolized by it. Enterococci are able to withstand conditions that are severely acidic (pH 9.6) and salty (high concentrations of salt) [22, 23]. They are impervious to bile salts, ethanol, azide, heavy metals, and detergents. Their optimal growth temperature range is 10–45 °C, and they can withstand 60 °C for 30 minutes.

Multiple drug resistance:

Aminoglycosides, aztreonam, and quinolones are among the most prominent antibiotic drugs that E. faecalis typically evades. The presence of several drug-resistance genes on the chromosome or

plasmid mediates the resistance. More and more E. faecalis strains are developing resistance to vancomycin [24]. Nitrofurantoin (for simple UTIs), linezolid, quinupristin, tigecycline, and daptomycin are all potential treatments for E. faecalis that has developed resistance to vancomycin; nonetheless, ampicillin is the drug of choice when the bacteria are susceptible. Although Enterococcus faecalis cannot be treated with quinupristin/dalfopristin, Enterococcus faecium may.

Medications used in combination:

In situations of severe infections (e.g., infections of the heart valves), one research found that combination medication therapy against susceptible strains of E. faecalis was somewhat effective. Gentamicin and ampicillin are effective against E. faecalis strains that are susceptible to ampicillin and vancomycin, meaning they do not possess a significant level of resistance to aminoglycosides [25]. For E. faecalis that is susceptible to ampicillin, an alternative that is less harmful to the kidneys is a combination of ampicillin and ceftriaxone. This combination works synergistically with ampicillin, even if E. faecalis is resistant to cephalosporins.

Markers of water quality for recreational purposes:

Recreational water facilities, such swimming pools and beaches that offer ocean swimming, frequently measure E. faecalis concentrations to evaluate water quality, due to the fact that E. faecalis is a prevalent faecal bacterium in humans. Water quality declines as concentration increases. Multiple studies have shown that higher concentrations of E. faecalis connect to increased percentages of swimmer sickness. As a result, the World Health Organisation (WHO) and many industrialised countries recommend adopting E. faecalis as a quality indicator. The measurement of E. faecalis concentrations to estimate water quality is applicable to all recreational waterways because this correlation is present in both freshwater and marine habitats [26, 27]. Even while there is a link, it doesn't mean E. faecalis is the main culprit when it comes to swimmers being sick. Another possible reason is that human viruses, which can make swimmers sick, are more prevalent in areas with greater concentrations of E. faecalis. Despite the seeming plausibility of this assertion, there is a lack of evidence linking E. faecalis to levels of human viruses or other infections. Therefore, additional research is necessary to establish the causal relationship between E. faecalis and water quality, even though there is a substantial correlation between the two.

Characteristics of Resistance:

A significant obstacle to therapy is the fact that Enterococcus spp. are both resistant and tolerant to a wide range of medicines. They are also adept at developing and spreading antibiotic resistance. The remarkable genetic plasticity of enterococci explains, in part, their ability to pick up mobile genetic components, form hybrid genomes with other enterococci, and even transmit genes between other species [28, 29]. Genes that are resistant to antibiotics seem to be more easily acquired when genomic defence mechanisms like CRISPR-Cas and resistance modification systems are not in place. It is well-known that plasmids and transposons allow for the transmission of genetic information, and that this process is known as horizontal gene transfer. The conjugative process is initiated by pheromones, which are mostly produced by E. faecalis but can also be observed in E. faecium [30]. Furthermore, E. faecalis receives a plethora of accessory genes from pheromone responsive plasmids, which is an essential function. The process of genetic information transfer by conjugation can also be attributed to non-pheromone-dependent plasmids. It has been found that these plasmids can transfer antibiotic resistance genes to bacteria that are not part of the enterococcal genus. In addition, research has demonstrated that plasmids can carry several genes that confer resistance to antibiotics [31]. Antibiotic resistance and several virulence

factors have been associated with these genes. Given that some plasmids were discovered exclusively in E. faecalis and not E. faecium, and vice versa, it is proposed that these plasmids developed host specificity in enterococcal species. Due to their ability to encode antibiotic-resistant genes, transposons have also been associated with drug resistance, namely to glycopeptides, gentamicin, and tetracycline [32]. Notable and often rapidly evolving is the resistance to vancomycin in Enterococcus spp. caused by gene clusters such vanA, B, C, D, and E. Clusters of genes that are resistant to vancomycin are able to do this via changing peptides that are building blocks of the cell wall, which are targets for vancomycin. The changed peptide termini make it so that vancomycin can't bind correctly, hence its affinity is low. Swaminathan et al. demonstrated an intriguing global variation in the prevalence of particular phenotypes of Enterococcus faecalis and E. faecium; specifically, vanA was isolated in North America and Europe, while vanB was detected in Asia and Australia. Resistance to vancomycin and teicoplanin have been demonstrated in the vanA phenotype. A tiny percentage of enterococcal infections are caused by E. gallinarum and E. casseliflavus/flavescens, two species that express the vanC gene and so have an intrinsic, low-level resistance to vancomycin [33]. Nosocomial infections caused by vancomycin-resistant enterococci (VRE) are widespread, and the most common strains are E. faecalis and E. faecium. There was a 21,000 percent increase in the number of VRE infections between 2000 and 2006. Sadly, horizontal gene transfer has been demonstrated to be an ability of enterococci to transmit antibiotic-resistant genes. Both in vitro and in vivo observations showed that enterococcus may transmit vanA to S. aureus. There have also been reports of enterococci causing methicillin-resistant Staphylococcus aureus to acquire vancomycin resistance [34]. Enterococcus is an important bacterium to study because of its characteristic.

The Ambulatory Population in Epidemiology:

A tiny fraction of community-associated infections are caused by enterococcus UTIs, however these infections are mostly nosocomial. A total of 1,119 individuals treated in outpatient clinics had their urine cultures taken as part of a cross-sectional study conducted by Malmartel et al. across multiple centres. Enterococcus spp. was detected in 7% of the cultures. E. faecalis was detected in 10.2% of the urine cultures obtained from 423 female patients with acute uncomplicated cystitis symptoms, according to a prospective study by Seitz et al. Although it is not as common, 5.3% of the ambulatory patients with UTIs who were studied by Laupland et al. had Enterococcus spp. isolated from their urine. Silva et al. observed an interesting difference in the prevalence of UTIs caused by E. faecalis between men (8.8%) and women (1.8%). According to this research, the sex of the patient should be taken into account when dealing with UTIs. Salm et al. conducted a retrospective, multicenter investigation wherein 102,736 male urine cultures were taken and examined in an outpatient environment. In 16.5% of the cultures, E. faecalis was found; in 22.9% of these cases, the infection was classified as polymicrobial. It is important to highlight that the prevalence of bacteria other than E. coli that cause UTIs in men is significant, as it can impact the selection of antibiotics. Bacterial resistance is more common in elderly patients, and it's especially more pronounced in male patients, which really drives the point home. There are a number of theories as to why men are more likely to get an Enterococcus infection than women. To start, males are prone to developing microscopic abscesses due to the presence of germs in their prostates. Germs can enter the prostate tissue through the intestines and seed it [35]. It has been proposed that the microbiota found in the prostate can influence the development of prostate cancer; furthermore, enterococcus has been discovered in sperm. Secondly, it is not unusual to encounter prostate stones. These stones may get secondary infections, which cause a biofilm to form on the stone and in the space around it. Although it has not been definitively demonstrated, urological studies have shown that reducing the frequency of

infections after removing stones from a prostate stone nidus and opening its crypts may be possible. Scientists have discovered a fundamental genetic difference between E. faecium strains recovered from nosocomial infections and those recovered from infections in the community. There are two main groups that these bacteria belong to: those that cause illnesses in healthcare settings (Clade A) and those that spread throughout the community (Clade B). One cross-sectional investigation aimed to identify the presence of VRE among ambulatory patients, while VRE has virtually exclusively been related with infections in hospitals. The study included 100 individuals. Out of the three patients that experienced colonisation, one did not get antibiotics recently and had no contact with a healthcare facility. The expansion of VRE outside of healthcare facilities limits treatment choices, which is a major concern for public health.

Patients at Risk (Those with Immunocompromised Diseases and Other Conditions)

Patients who already have many health conditions are at a greater risk, as we discussed earlier. The development of complex UTIs becomes much more significant when patients are immunocompromised, as is the case with organ transplant and cancer patients [36]. With nearly half of patients developing bacteriuria, UTIs are among the most common ailments in the first year after renal transplant. High rates of multidrug resistance were also shown by the principal causing pathogens, E. coli and enterococcus, which accounted for 35% of all UTIs. Although it is often discouraged, the authors recommend treating ASB in renal transplant patients due to the risk it poses to these susceptible individuals. Additionally, the practice of treating transplant patients with ASB was further validated by Swaminathan et al. [36]. The risk of VRE is increased when enterococcus colonisation leads to symptomatic illness. Prevention and early treatment should be attempted even in the absence of symptoms because to the high rate of mutagenicity with enterococcus and the limited therapeutic options for VRE, as previously mentioned.

Medical Care:

Because enterococci are prone to developing resistance to multiple drugs, determining susceptibility is crucial for selecting the right antibiotic treatment for managing urinary infections caused by this bacteria. Because different species have different resistance patterns and virulence factors, it is important to know which species is causing the infection in order to formulate an appropriate treatment approach. It is important to have solid clinical evidence that the patient is suffering from a symptomatic UTI and not ASB before prescribing antibiotics. It has already been mentioned in the review that antibiotics should only be administered to specific people in order to treat ASB. The large concentration of ampicillin in urine makes it effective, even if some bacteria have developed resistance. Amoxicillin and nitrofurantoin were equally effective in treating ampicillin-resistant E. faecium, according to one research [37]. Furthermore, nitrofurantoin was found to be susceptible to UTIs caused by VRE in vitro [38,53,54]. It is recommended to utilise amoxicillin, fosfomycin, or nitrofurantoin for the treatment of simple infections [55].

Additional options for treatment include ampicillin, fluoroquinolones, oxazolidinones, vancomycin, and daptomycin in cases when susceptibility testing reveals otherwise. A combination of intravenous ampicillin, fluoroquinolones, oxazolidinones, vancomycin, and daptomycin can be administered to patients with more complex infections. A combination of ampicillin with streptomycin or gentamicin is suggested for more serious infections, though.

Importance of the Surface Protein Esp from Enterococcus faecalis:

Numerous host biological and behavioural variables, as well as characteristics of the infecting

uropathogens, contribute to the convoluted pathophysiology of both simple and complex urinary tract infections (UTIs). Some of the most common bacteria that can cause urinary tract infections (UTIs) are Pseudomonas aeruginosa, Candida albicans, Escherichia coli, Enterococcus faecalis, and Proteus mirabilis. Urinary tract infections (UTIs) caused by Escherichia coli have been on the rise, and infections caused by MRSA are a major health concern (11). Chronic or recurring UTIs, particularly those linked to structural abnormalities and instrumentation, are frequently caused by Enterococcus spp., which ranks third among the most prevalent bacteria recovered from patients with UTIs in the intensive care unit [38]. There is a lack of knowledge on the bacterial components that contribute to nosocomial UTIs, despite the fact that E. faecalis is a major culprit in this regard. In the past, researchers have looked at enterococci and uroepithelial tissue in an effort to find out how enterococci adhere to renal epithelial cells in vitro using a plasmid-encoded aggregation material. Guzman and colleagues demonstrated that E. faecalis isolates from UTIs adhered more well to urinary tract epithelial cells than to Girardi heart cells in a study comparing E. faecalis isolates from people with UTIs and endocarditis. However, elevating the bacterial growth in human blood eightfold increased the adhesion of UTI isolates to Girardi cardiac cells. Bacterial cell surface carbohydrates and proteins seem to play a role in the intricate nature of the interaction between enterococci and uroepithelial tissue. Although the Esp protein is uncommon in faecal isolates of E. faecalis, it is expressed by approximately one-third of E. faecalis isolates from patients with bacteremia and UTIs, indicating that this surface protein may have a significant role in these illnesses. Many bacterial surface protein adhesins that bind to host ligands share the same distinctive architecture as the Esp protein, which features many repeat motifs.

Much more has to be understood regarding the pathogenicity of E. faecalis, even though it has been acknowledged as a significant uropathogen. Extensive research on Escherichia coli and Proteus mirabilis, the two most common types of community-acquired UTIs, has revealed distinct characteristics displayed by individual UTI isolates. Highly adapted uropathogenic bacteria have features including P fimbriae, hemolysin, serum resistance, and encapsulation that help them colonise the bladder, survive in the urinary tract, and sometimes even cause tissue damage. A crucial first stage in the pathophysiology of UTIs is adhesion to the bladder epithelium, which has been well-established. The initial adhesion that prevents washout by urine flow is mediated by type 1 fimbriae, P and related fimbriae, and F1C fimbriae in E. coli. The uroepithelium is rich with receptors that type 1 fimbriae bind to, which contain mannose, while type P fimbriae bind to receptors that carry the Gala(1-4)Gal component of the P blood group and similar ones (31). Glycolipids asialoGM1 (GgO4Cer) and asialo-GM2 (GgO3Cer) bind with high affinity to the GalNAcb1-4Galb sequence, while the carbohydrate structures GlcNAcb1-3Galb, Galb1–4Glc, Gal, and Glc bind with low affinity.

One unique thing about the Esp protein is that the structural esp gene encodes two huge repeat motifs that are almost identical to each other. These motifs consist of 82 and 84 amino acids, respectively. The genetic process of homologous recombination inside these repeat units can increase or decrease the amount of the encoded protein by adding or removing repeat units. There are different sized variants of the Esp protein that are expressed by different E. faecalis isolates, and this variation is proportional to the number of repeating units [39]. An environment-specific role for Esp could be defined by its fluctuation in size at the cell surface, according to the postulation. In the early phases of infection, an elongated version of the Esp protein may engage with host receptors via adhesion functions. Similar to how uropathogenic E. coli exhibits phase variation, Esp may express a shorter version of its surface protein after establishing itself in the host in order to elude the immune response; this shorter version

may be more beneficial to survival and persistence.

How to Treat Enterococcal Urinary Tract Infections Caused by Resistant Bacteria

Urinary tract infections (UTIs), particularly in hospitalised patients, are increasingly caused by Enterococcus spp. Infections caused by Enterococcus faecium are especially prone to the development of resistance to vancomycin and other antibiotics. With few effective treatments for multidrug-resistant (MDR) Enterococcus and many patients suffering from co-morbidities, the management of UTIs caused by this bacterium has become more difficult. Asymptomatic bacteriuria caused by multidrug-resistant Enterococcus should not be treated routinely. It is worth considering the possibility of removing indwelling urinary catheters. Results from urine cultures and susceptibility tests should be used to choose the right antibiotic treatment. Few details are known on how to treat UTIs caused by MDR-Enterococcus. Nitrofurantoin, fosfomycin, and fluoroquinolones are oral medicines that are effective against methicillin-resistant Enterococcus bacteria. They may be explored for the treatment of acute, uncomplicated UTIs. Parenteral medications such as daptomycin, linezolid, and quinipristin-dalfopristin have the potential to treat pyelonephritis and complex UTIs caused by MDR-Enterococcus. As an additional course of treatment, rifampin or aminoglycosides can be recommended for severe infections.

The global prevalence of urinary tract infections (UTIs) is unparalleled.1 When it comes to simple UTIs, enterococcus species is among the most common culprits. Amoxicillin and ampicillin, which are aminopenicillin (AP) antibiotics, are now the medications that the Infectious Diseases Society of America recommends for the treatment of enterococcus UTIs.2 The incidence of bacteria that are resistant to ampicillin has been on the rise. Notably, 30% of clinical enterococcal isolates have been found to be resistant to vancomycin, and the incidence of vancomycin-resistant enterococci (VRE) has virtually doubled in the past few years. The current criteria set by the Clinical and Laboratory Standards Institute states that Enterococcus species are classified ampicillin-resistant if their minimum inhibitory concentration (MIC) is equal to or more than 16 μg/mL. No matter where an infection has occurred, microbiology labs always utilise this same cutoff. Although some enterococcus UTI isolates may have a minimum inhibitory concentration (MIC) higher than the susceptibility breakpoint, pharmacologic and pharmacokinetic studies as well as results from clinical trials suggest that aminopenicillin antibiotics can be effective in treating these infections [40]. We can attain far larger concentrations in the urine than in the blood stream when using AP antibiotics since they are eliminated through the kidneys. An average concentration of 1100 μg/mL in urine collected over 6 hours following a single 500 mg oral dose of amoxicillin was shown in one investigation. In a separate investigation, research looked at E. Faecium urine isolates that were resistant to ampicillin and had minimum inhibitory concentrations (MICs) of 128 μg/mL (30%), 256 μg/mL (60%), and 512 Δg/mL (10%). Evidence from these studies suggests that AP concentrations in the urinary system are high enough to cure a number of illnesses that have shown resistance.

The MICs of ampicillin-resistant E. faecium urine isolates were determined to be varied in another investigation, with a median MIC of 256 μg/mL5. Though only five of the isolates showed MIC values greater than 1000 μg/mL, all five were within one dilution of 512 μg/mL. The killing effect of penicillin antibiotics varies with the passage of time; for best response, the urine concentration should remain higher than the minimum inhibitory concentration (MIC) for half of the dosage interval. For this reason, it is safe to assume that, at therapeutic doses, AP antibiotics will eradicate not just Enterococcus species but also ampicillin-resistant enterococcus found in less severe UTIs. One strategy to reduce the usage of broad-spectrum antibiotics like linezolid and daptomycin to treat these infections is to educate prescribers [41]. The development of institutional

protocols to assist prescribers in moving towards guideline-directed prescribing is an additional option. A microbiology lab is a good place to start fighting this problem. Better susceptibility data would be available with urine-specific breakpoints, but they are currently not routinely used. It has been reported that all enterococcus urine isolates are routinely susceptible to aminopenicillins, and many hospitals have stopped testing for this susceptibility.6 Researchers in one study examined the effectiveness of AP antibiotics with non-beta-lactam antibiotics in treating VRE UTIs. The study did not take ampicillin susceptibility into account when determining whether AP treatment was active or not. Amoxicillin was chosen as the definitive treatment for the majority of patients in the AP group, with intravenous ampicillin, ampicillin-sulbactam, and amoxicillin-clavulanate following closely behind [42–46]. Linezolid, daptomycin, and fosfomycin were the most often chosen agents for definitive therapy in the non-beta-lactam group. Patients treated with AP had an 83.9% clinical cure rate, compared to 73.3% in the non-beta-lactam group. According to references [47–49], 86% of patients with ampicillin-resistant isolates and 84% of all cases were cured clinically with AP therapy. There was no significant difference in the outcomes for patients treated with non-β-lactams. It is reasonable to believe that aminopenicillin antibiotics, including amoxicillin and ampicillin, reach enough urine concentrations to eliminate E. species, independent of ampicillin susceptibility, based on pharmacokinetic evidence from multiple clinical trials. Important first measures include educating doctors and chemists on PK/PD data, antibiotic sensitivities, and clearance.

Conclusions:

Nosocomial and community-acquired UTIs caused by enterococci have both been on the rise in recent years. A wide number of mechanisms, including biofilm formation and genetic malleability, contribute to Enterococcus's distinctive and ever-increasing pathogenicity. The fundamentals of biofilm production by some enterococcal species are recognised, but much remains unclear. A substantial threat to public health might result from the pathogenicity of these bacteria and the domino effect they can set in motion. It is critical to keep focusing on and investigating these distinct mechanisms because antibiotic resistance is on the rise and new therapies are being developed at a slower rate. There has to be more thought and care put into the treatment plan for enterococcal infections than usual.

References:

1. Kreft B, Marre R, Schramm U, Wirth R (January 1992). "Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells". Infection and Immunity. **60** (1): 25–30.
2. Huycke, M. M., D. F. Sahm, and M. S. Gilmore. 1998. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg. Infect. Dis. 4:239–249.
3. Huycke, M. M., C. A. Spiegel, and M. S. Gilmore. 1991. Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 35:1626–1634.
4. Johnson, D. E., R. G. Russell, C. V. Lockatell, J. C. Zulty, J. W. Warren, and H. L. Mobley. 1993. Contribution of Proteus mirabilis urease to persistence, urolithiasis, and acute pyelonephritis in a mouse model of ascending urinary tract infection. Infect. Immun. 61:2748–2754.
5. Johnson, J. R. 1991. Virulence factors in Escherichia coli urinary tract infection. Clin. Microbiol. Rev. 4:80–128.
6. Khan, A. S., B. Kniep, T. A. Oelschlaeger, I. Van Die, T. Korhonen, and J. Hacker. 2000. Receptor structure for F1C fimbriae

of uropathogenic Escherichia coli. Infect. Immun. 68:3541–3547.

7. Kreft, B., R. Marre, U. Schramm, and R. Wirth. 1992. Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect. Immun. 60:25–30.
8. Lewis, C. M., and M. J. Zervos. 1990. Clinical manifestations of enterococcal infection. Eur. J. Clin. Microbiol. Infect. Dis. 9:111–117.
9. Li, J., D. L. Kasper, F. M. Ausubel, B. Rosner, and J. L. Michel. 1997. Inactivation of the alpha C protein antigen gene, bca, by a novel shuttle/ suicide vector results in attenuation of virulence and immunity in group B streptococcus. Proc. Natl. Acad. Sci. USA 94:13251–13256.
10. Mobley, H. L., M. D. Island, and G. Massad. 1994. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis. Kidney Int. Suppl. 47:S129–S136. 20. Mobley, H. L. T. 2000. Virulence of the two primary uropathogens. ASM News 66:403–410.
11. Hirt H, Schlievert PM, Dunny GM (February 2002). "In vivo induction of virulence and antibiotic resistance transfer in Enterococcus faecalis mediated by the sex pheromone-sensing system of pCF10". Infection and Immunity. **70** (2): 716–723.
12. Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP (June 2019). "Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism". Science. **364** (6445): eaau6323.
13. Singh H, Das S, Yadav J, Srivastava VK, Jyoti A, Kaushik S (October 2019). "In search of novel protein drug targets for treatment of Enterococcus faecalis infections". Chemical Biology & Drug Design. **94** (4). Wiley: 1721–1739.
14. Amyes SG. "Enterococci and streptococci". International Journal of Antimicrobial Agents. **29** (Suppl 3): S43–S52.
15. Courvalin P (January 2006). "Vancomycin resistance in gram-positive cocci". Clinical Infectious Diseases. **42** (Suppl 1): S25–S34.
16. Zhanel GG, Hoban DJ, Karlowsky JA (January 2001). "Nitrofurantoin is active against vancomycin-resistant enterococci". Antimicrobial Agents and Chemotherapy. **45** (1): 324–326.
17. Arias CA, Contreras GA, Murray BE (June 2010). "Management of multidrug-resistant enterococcal infections". Clinical Microbiology and Infection. **16** (6): 555–562.
18. Dunny, G.M.; Hancock, L.E.; Shankar, N. Enterococcal Biofilm Structure and Role in Colonization and Disease. In Enterococci: From Commensals to Leading Causes of Drug Resistant Infection; Gilmore, M.S., Clewell, D.B., Ike, Y., Eds.; Eye and Ear Infirmary: Boston, MA, USA, 2014.
19. García-Solache, M.; Rice, L.B. The Enterococcus: A Model of Adaptability to Its Environment. Clin. Microbiol. Rev. 2019, 32, e00058-
20. Ch'ng, J.H.; Chong, K.K.L.; Lam, L.N.; Wong, J.J.; Kline, K.A. Biofilm-associated infection by enterococci. Nat. Rev. Microbiol. 2018, 17, 82–94.
21. Delcaru, C.; Alexandru, I.; Podgoreanu, P.; Grosu, M.; Stavropoulos, E.; Chifiriuc, M.C.; Lazar, V. Microbial Biofilms in Urinary Tract Infections and Prostatitis: Etiology, Pathogenicity, and Combating strategies. Pathogens 2016, 5,
22. Tien, B.Y.Q.; Goh, H.M.S.; Chong, K.K.L.; Bhaduri-Tagore, S.; Holec, S.;

Dress, R.; Ginhoux, F.; Ingersoll, M.A.; Williams, R.B.H.; Kline, K.A. Enterococcus faecalis Promotes Innate Immune Suppression and Polymicrobial Catheter-Associated Urinary Tract Infection. Infect. Immun. 2017, 85, e00378-17.

23. Sharma, A.K.; Dhasmana, N.; Dubey, N.; Kumar, N.; Gangwal, A.; Gupta, M. Bacterial Virulence Factors: Secreted for Survival. Indian J. Microbiol. 2016, 57, 1–10.

24. Shankar, N.; Lockatell, C.V.; Baghdayan, A.S.; Drachenberg, C.; Gilmore, M.S.; Johnson, D.E. Role of Enterococcus faecalis Surface Protein Esp in the Pathogenesis of Ascending Urinary Tract Infection. Infect. Immun. 2001, 69, 4366–4372.

25. Hashem, Y.A.; Abdelrahman, K.A.; Aziz, R.K. Phenotype–Genotype Correlations and Distribution of Key Virulence Factors in Enterococcus faecalis Isolated from Patients with Urinary Tract Infections. Infect. Drug Resist. 2021, 14, 1713–1723.

26. Süßmuth, S.D.; Muscholl-Silberhorn, A.; Wirth, R.; Susa, M.; Marre, R.; Rozdzinski, E. Aggregation Substance Promotes Adherence, Phagocytosis, and Intracellular Survival of Enterococcus faecalis within Human Macrophages and Suppresses Respiratory Burst. Infect. Immun. 2000, 68, 4900–4906.

27. Coburn, P.S.; Gilmore, M.S. The Enterococcus faecalis cytolysin: A novel toxin active against eukaryotic and prokaryotic cells. Cell. Microbiol. 2003, 5, 661–669.

28. Nallapareddy, S.R.; Qin, X.; Weinstock, G.M.; Höök, M.; Murray, B.E. Enterococcus faecalis Adhesin, Ace, Mediates Attachment to Extracellular Matrix Proteins Collagen Type IV and Laminin as well as Collagen Type I. Infect. Immun. 2000, 68, 5218–5224.

29. Toledo-Arana, A.; Valle, J.; Solano, C.; Arrizubieta, M.J.; Cucarella, C.; Lamata, M.; Amorena, B.; Leiva, J.; Penade, R.; Lasa, I. The Enterococcal Surface Protein, Esp, Is Involved in Enterococcus faecalis Biofilm Formation. Appl. Environ. Microbiol. 2001, 67, 4538–4545.

30. Levitus, M.; Rewane, A.; Perera, T.B.; Vancomycin-Resistant Enterococci. PubMed. 2021.

31. Perichon, B.; Courvalin, P. VanA-Type Vancomycin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53, 4580–4587.

32. Chang, S.; Sievert, D.M.; Hageman, J.C.; Boulton, M.L.; Tenover, F.C.; Downes, F.P.; Shah, S.; Rudrik, J.T.; Pupp, G.R.; Brown, W.J. Infection with Vancomycin-Resistant Staphylococcus aureus Containing the van AResistance Gene. N. Engl. J. Med. 2003, 348, 1342–1347.

33. Miller, W.R.; Munita, J.M.; Arias, C.A. Mechanisms of antibiotic resistance in enterococci. Expert Rev. Anti-Infect. Ther. 2014, 12, 1221–1236.

34. Pogliano, J.; Pogliano, N.; Silverman, J.A. Daptomycin-Mediated Reorganization of Membrane Architecture Causes Mislocalization of Essential Cell Division Proteins. J. Bacteriol. 2012, 194, 4494–4504.

35. Naber, K.G.; Schito, G.; Botto, H.; Palou, J.; Mazzei, T. Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy. Eur. Urol. 2008, 54, 1164–1178.

36. Malmartel, A.; Ghasarossian, C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur. J. Clin. Microbiol. Infect. Dis. 2016, 35, 447–451.

37. Seitz, M.; Stief, C.; Waidelich, R. Local epidemiology and resistance profiles in acute uncomplicated cystitis (AUC) in women: A prospective cohort study in an urban urological ambulatory setting. BMC Infect. Dis. 2017, 17, 685.

38. Laupland, K.B.; Ross, T.; Pitout, J.D.D.; Church, D.L.; Gregson, D.B. Community-onset Urinary Tract Infections: A Populationbased Assessment. Infection 2007, 35, 150–153.

39. Silva, A.; Costa, E.; Freitas, A.; Almeida, A. Revisiting the Frequency and Antimicrobial Resistance Patterns of Bacteria Implicated in Community Urinary Tract Infections. Antibiotics 2022, 11, 768.

40. Salm, J.; Salm, F.; Arendarski, P.; Kramer, T.S. High antimicrobial resistance in urinary tract infections in male outpatients in routine laboratory data, Germany, 2015 to 2020. Eurosurveillance 2022, 27, 2101012.

41. Xiong, S.; Liu, X.; Deng, W.; Zhou, Z.; Li, Y.; Tu, Y.; Chen, L.; Wang, G.; Fu, B. Pharmacological Interventions for Bacterial Prostatitis. Front. Pharmacol. 2020, 11, 504.

42. Che, B.; Zhang, W.; Xu, S.; Yin, J.; He, J.; Huang, T.; Li, W.; Yu, Y.; Tang, K. Prostate Microbiota and Prostate Cancer: A New Trend in Treatment. Front. Oncol. 2021, 11, 5260.

43. Balzan, S.; de Almeida Quadros, C.; de Cleva, R.; Zilberstein, B.; Cecconello, I. Bacterial translocation: Overview of mechanisms and clinical impact. J. Gastroenterol. Hepatol. 2007, 22, 464–471.

44. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003 Feb;49(2):53-70. doi: 10.1067/mda.2003.7. PMID: 12601337.

45. Ramsey AM, Zilberberg MD. 2009. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000–2006. Infect Control Hosp Epidemiol 30:184–186.

46. Cole KA, Kenney RM, Perri MB, Dumkow LE, Samuel LP, Zervos MJ, Davis SL. Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections. Antimicrob Agents Chemother. 2015 Dec;59(12):7362-6.

47. Williamson JC, Craft DW, Butts JD, Raasch RH. In vitro assessment of urinary isolates of ampicillin-resistant enterococci. Ann Pharmacother. 2002;36(2):246–250.

48. Dumkow LE, Perri MB, Zervos M. Time to stop using alternatives to ampicillin for enterococcal UTIs? In-vitro susceptibility trends for enterococcus urinary isolates over a one-year period in Detroit. Poster presented at: 53rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC).